Mer­ck falls short in PhI­II Covid-19 pro­phy­lax­is tri­al, join­ing Pfiz­er

Mer­ck took an­oth­er swing at bat to bol­ster its case for its Covid-19 an­tivi­ral — and that swing turned in­to yet an­oth­er miss.

The phar­ma gi­ant …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.